The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMcbride Regulatory News (MCB)

Share Price Information for Mcbride (MCB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 111.00
Bid: 110.00
Ask: 111.00
Change: 0.00 (0.00%)
Spread: 1.00 (0.909%)
Open: 114.50
High: 114.50
Low: 109.50
Prev. Close: 111.00
MCB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

30 Jun 2014 07:00

RNS Number : 8336K
McBride PLC
30 June 2014
 



30th June 2014

 

McBride PLC

Trading Update

 

McBride PLC, Europe's leading provider of Private Label Household and Personal Care products, today provides an update on trading for the year ended 30th June 2014 prior to entering its close period, and is also communicating an update with regard to the strategic review of its UK business.

 

The Board expects to report adjusted operating profit and net debt for the year just ended in line with its expectations indicated by the previous trading statement.

 

Group full year revenue on a constant currency basis is expected to show a decline of 3% as previously announced. Private Label revenue was flat with continued growth in our France/Benelux, Poland and Germany businesses, the latter driven by significant new business wins, offset by the effects of the weak retail environment in the UK and Italy and continued increased branded promotional activity. Contract revenue declined by 20% as expected due to the winding down of certain contracts.

 

As previously announced, and in response to a deterioration in the retail environment in UK, the Board is conducting a wide-ranging strategic review of its UK business. The Board is today announcing further opportunities to restructure the Group's activities, remove un-profitable business and reduce capacity in the UK in order to improve profitability. Savings of around £12 million are expected to be delivered in full by June 2016 with around £3 million benefitting FY15. Associated cash implementation costs are expected to be around £14 million. Regrettably, it is expected that, of a workforce of 1,600 in the UK business, around 400 positions are expected to be made redundant. Consultation with affected employee groups will start immediately.

 

As a consequence of the review, the Board expects to impair the value of assets in UK by £21 million, including £6 million of goodwill, in the current financial year.

 

In addition, the Group expects to incur material one-off costs in relation to two matters. The implementation of the European Classification, Labelling and Packaging regulations will lead to exceptional costs of around £4m as a consequence of the need to re-configure the labelling of almost all the Group's products. The Group is also expected to take an exceptional charge of £2.5m in relation to a long term environmental remediation plan at a site in Belgium.

 

For the 2015 year, underlying growth in Group revenue of 2% is expected, although this will be offset by the exiting of un-profitable business as part of the UK re-structuring. Net debt at June 2015 is expected to be in the range £105 million to £110 million, leaving significant headroom within the Group's borrowing facilities. Total exceptional charges will amount to around £37 million in FY14 and £7 million in FY15, including the impairment noted above and final costs in relation to existing savings programmes.

 

The Group intends to announce its preliminary results for the year ended 30th June 2014 on 10th September 2014.

 

Chris Bull, Group Chief Executive Officer, commented:

 

"We are announcing a robust plan that will help restore our UK profitability. We will exit some business in non-core un-profitable categories, but our capacity to meet growth opportunities in our core categories remains unaffected. We will be entering into full and meaningful consultation with colleagues affected by these proposals".

 

 

For further information please contact:

 

McBride plc

Chris Bull, Chief Executive

020 3642 1587

Richard Armitage, Group Finance Director

020 3642 1587

FTI Consulting

Ed Bridges, Nick Hasell

020 3727 1017

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBKLLLZQFBBBZ
Date   Source Headline
2nd May 20249:21 amRNSHolding(s) in Company
30th Apr 20247:00 amRNSTrading Update
8th Apr 202411:24 amRNSHolding(s) in Company
8th Apr 202411:22 amRNSHolding(s) in Company
5th Apr 20249:53 amRNSHolding(s) in Company
28th Mar 20243:20 pmRNSDirector/PDMR Shareholding
25th Mar 20241:52 pmRNSDirector/PDMR Shareholding
13th Mar 20247:00 amRNSCapital Markets Day
28th Feb 20242:30 pmRNSDirector/PDMR Shareholding
27th Feb 20247:00 amRNSHalf-year Report
16th Jan 20247:00 amRNSTrading Update
13th Dec 20231:47 pmRNSDirector/PDMR Shareholding
20th Nov 20235:55 pmRNSDirector/PDMR Shareholding
20th Nov 20235:39 pmRNSResult of AGM
20th Nov 20237:00 amRNSAGM Trading Update
25th Oct 202310:22 amRNSTermination of ‘upside sharing’ mechanism
19th Oct 20237:00 amRNSTrading Update
17th Oct 20235:42 pmRNSPosting of ARA and Notice of AGM
4th Oct 20235:24 pmRNSVesting of RSU Awards
29th Sep 20237:00 amRNSDirector/PDMR Shareholding
22nd Sep 20235:33 pmRNSDirector/PDMR Shareholding
21st Sep 202310:54 amRNSDirector/PDMR Shareholding
19th Sep 20237:00 amRNSFinal Results
14th Jul 20237:00 amRNSFull year trading update
13th Jun 20237:00 amRNSDirector/PDMR Shareholding
31st May 20235:31 pmRNSDirectorate Change
25th May 20239:38 amRNSDirector Declaration
2nd May 20237:00 amRNSDirector/PDMR Shareholding
25th Apr 20237:00 amRNSTrading Update
11th Apr 20232:08 pmRNSDirector/PDMR Shareholding
3rd Apr 20232:39 pmRNSDirector/PDMR Shareholding
31st Mar 202312:27 pmRNSDirector/PDMR Shareholding
21st Mar 20235:59 pmRNSDirector/PDMR Shareholding
28th Feb 20237:00 amRNSHalf-year Report
1st Feb 20234:40 pmRNSSecond Price Monitoring Extn
1st Feb 20234:35 pmRNSPrice Monitoring Extension
1st Feb 20238:46 amRNSDirector Declaration
17th Jan 20237:00 amRNSTrading Update
11th Jan 20239:01 amRNSDirector Declaration
22nd Dec 20224:23 pmRNSDirector/PDMR Shareholding
13th Dec 20222:51 pmRNSDirector/PDMR Shareholding
16th Nov 20224:42 pmRNSAGM Statement
16th Nov 20227:00 amRNSAGM Trading Update
17th Oct 20227:00 amRNSAnnual Report 2022 and Annual General Meeting 2022
5th Oct 20225:55 pmRNSDirector/PDMR Shareholding
3rd Oct 20225:07 pmRNSRedemption of B Shares
29th Sep 202212:49 pmRNSFinal Results
29th Sep 202211:51 amRNSAmended Financing Agreement
29th Sep 20227:00 amRNSPreliminary results timing
6th Sep 20222:51 pmRNSBoard Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.